Research programme: non-cardiovascular therapies - Forbes Medi-Tech/KineMed
Latest Information Update: 27 May 2008
At a glance
- Originator Forbes Medi-Tech; KineMed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 27 May 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 11 Apr 2006 Preclinical trials in Undefined in USA (unspecified route)